Comparative Pharmacology
Head-to-head clinical analysis: OLANZAPINE AND FLUOXETINE HYDROCHLORIDE versus ZYPREXA RELPREVV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLANZAPINE AND FLUOXETINE HYDROCHLORIDE versus ZYPREXA RELPREVV.
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE vs ZYPREXA RELPREVV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). The combination modulates serotonergic and dopaminergic pathways to treat depressive episodes in bipolar I disorder.
Olanzapine pamoate is a second-generation antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also binds to adrenergic α1, histamine H1, and muscarinic M1 receptors.
Olanzapine 6 mg / fluoxetine 25 mg orally once daily in the evening, with dose adjustments based on response and tolerability.
210 mg intramuscular injection every 2 weeks; range 150-300 mg; max 300 mg per dose. For olanzapine-naive patients, establish tolerability with oral olanzapine before initiation.
None Documented
None Documented
Olanzapine: 30 h (young adults); 50 h (elderly). Fluoxetine: 4-6 days (single dose), 4-6 days (norfluoxetine); longer with chronic dosing (up to 6-8 weeks to steady state). Clinical context: drug accumulates over weeks.
The terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) after intramuscular injection, consistent with extended release from the depot formulation.
Olanzapine: ~57% renal (metabolites), ~30% fecal. Fluoxetine: ~80% renal (metabolites, mainly norfluoxetine), ~15% fecal.
Approximately 57% of the dose is excreted in urine (30% as unchanged drug, 27% as metabolites) and 30% in feces (primarily as metabolites).
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic